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1. Introduction
For several years, prostate cancer (PCa) has been considered a genetic disease, driven by
somatic mutations occurring at critical oncogenic or tumor suppressive loci [1]. This view
has changed over the last decades, thanks to mounting evidence on the role of epigenet‐
ics  in  PCa  initiation  and  progression  [2].  The  term “epigenetics”  derives  from a  Greek
word, and literally means “above the gene”. In molecular biology, this definition includes
all heritable gene expression patterns, which are not derived from an alteration of DNA
primary sequence [3].  The first  epigenetic  alteration to be linked with cancer was DNA
methylation, which occurs at 5-cytosine residues in specific genomic regions, called CpG
islands [2, 4]. Cytosine methylation results in gene silencing, especially when occurring at
the promoter region of a targeted locus. This process is mediated by enzymes called DNA
methyltransferases (DNMTs) [5]. Functional studies demonstrated that, along with inacti‐
vating mutations, DNA methylation is an alternative way of tumor suppressor silencing,
and that this event might even anticipate the occurrence of a genetic mutation. For exam‐
ple, the PTEN  (Phosphatase and tensin homolog) gene encodes for a phosphatase which
acts  as  a  potent  tumor  suppressor  in  PCa  [6].  Indeed,  PTEN  protein  is  able  to  inhibit
AKT (protein  kinase  B),  which  in  turn  activates  several  anti-apoptotic  and proliferative
signals in PCa cells. In keeping with these observations, PTEN- knockout mice display an
early onset of  PCa [7].  PTEN  inactivating mutations are found in approximately 20% of
PCa samples, and are associated with hormone refractory disease and higher tumor stage
[8]. However, PTEN  mutation is rarely homozygous, and approximately 50% of PCa pa‐
tients  are  PTEN-negative,  even if  they  do not  display  any genetic  alteration [9].  Subse‐
quent studies found that DNA methylation is the main mechanism of PTEN  silencing in
PCa, as well as in other neoplasms [10]. This event may occur in association with muta‐
tion  on  the  other  allele  [11].  DNA methylation  in  the  PTEN  promoter  region  acts  as  a
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docking  site  for  MeCP2 (methyl-CpG-binding  protein  2),  which  in  turn  recruits  several
chromatin remodelling factors.  Those complexes are able  to turn transcriptionally active
chromatin (euchromatin) into an inactive form (heterochromatin) [12]. Since then, several
tumor suppressor genes were shown to be methylated in a significant fraction of PCa pa‐
tients [13].  DNA methylation patterns are useful biomarkers for early diagnosis and pa‐
tient stratification. Unlike genetic alterations,  epigenetic changes are reversible,  and thus
can be targeted by specific drugs [2]. DNMT inhibition is able to reactivate silenced onco‐
genes,  thereby inducing apoptosis and reducing treatment resistance [14].  Pharmacologi‐
cal  inhibitors  of  DNMTs have been developed and tested in clinical  trials,  and some of
them are approved for the treatment of haematological malignancies [15]. In PCa, as well
as  in  other  solid  tumors,  DNMT inhibitors  displayed encouraging effects  in  pre-clinical
models [14], but often failed to demonstrate clinically relevant activity [16]. One possible
explanation for this discrepancy is that DNA methylation is not the key epigenetic mech‐
anism in PCa.
As basic research on epigenetic gene regulation proceeds, it is becoming increasingly clear
that gene expression regulation in human cells is finely tuned by the concurrent activity of
different protein complexes. To understand the foundation of this intricate process, it is nec‐
essary to consider the tridimensional structure of chromatin [17]. The nucleosome is the ba‐
sic chromatin unit. It is composed by approximately 150 bp of DNA, which are wrapped
around a cylindrical protein complex (histone core) [18]. The core is an octamer composed of
two copies of histone H2a, H2b, H3 and H4. Histone H1 acts as a linker between two nucleo‐
somes. Nucleosomes can restrict the access of RNA polymerases to the DNA; thus, their lo‐
cal interaction with DNA is critical for gene expression control. Histones are characterized
by long N-terminal tails, which mainly interact with the DNA phosphate backbone [19]. For
this reason, post-translational modifications at histone tails can shape the local tridimension‐
al structure of chromatin, thereby affecting RNA polymerase (and transcription factor) ac‐
cessibility, and eventually modifying gene expression. Seminal studies revealed that the
range of possible histone post-translational modifications (HPTMs) is wide, including acety‐
lation, methylation, phosphorylation, ubiquitination, sumoylation and ADP-ribosylation
[20]. Another layer of complexity is represented by the variable number of amino-acidic resi‐
dues that can be modified. In addition, some modifications may be repeated on the same
residue. For example, histone H3 Lys 27 (H3K27) can be mono-, di- or tri-methylated (me)
[19]. Each single modification affects gene activity, and likely interacts with others [20]. As it
is easy to understand, the combinatorial complexity of those modifications is immense, and
we still lack appropriate technologic tools to comprehensively investigate this phenomenon
[21]. Some authors proposed the systematic discovery of the histone code, i.e. the hidden
language by which HPTMs cooperate to determine local gene activity [22].
Despite this discouraging complexity, some research sheds light on the functional role of
specific HPTMs. For example, it is well known that histone lysine acetylation loosens DNA-
histone binding, thereby providing transcriptionally active chromatin [23]. Accordingly, his‐
tone acetylases (HATs) are a class of activating epigenetic modifiers [24]. For the same
reason, histone deacetylases (HDACs) are enzymes that repress gene expression [25]. To the
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contrary, histone methylation is multifaceted, since it can be associated with gene repression
or activation depending on the targeted amino acid residue. For example, H3K9me and
H3K27me are repressive marks, while H3K4me and H3K36me activate gene expression [26].
Interestingly, most of those HPTMs are mediated by two classes of histone modifiers, which
appear to act as counteracting forces during embryonic development, and are emerging as
novel oncogenes and tumor suppressor genes. The first class to be discovered was the Poly‐
comb group (PcG) genes, which are mainly organized in multimeric Polycomb repressive
complexes 1 and 2 (PRC1 and PRC2; Table 1) [27]. PRC2 catalyzes H3K27 trimethylation
(me3), which acts as a docking site for PRC1. The latter complex then catalyzes histone
H2aK119 ubiquitination (ub). Both modifications are repressive marks, and can be associat‐
ed with DNA methylation [28]. In addition, it has been shown that PRC1 can act independ‐
ently of PRC2 [29]. The function of PRCs was revealed by mutational analyses conducted on
Drosophila. PRCs are essential for HOX (homeobox) gene silencing and tissue specification
[30]. Drosophila PRC homologs are also expressed in human cells, where they regulate stem
cell function and differentiation. Studies on human cells also revealed that PRCs can target a
wider set of genes, and that they are involved in physiologic and pathologic phenomena, in‐
cluding cancer [31]. In PCa, both PRC1 and PRC2 display oncogenic functions, through the
repression of key tumor suppressor genes. For example, PRC1 member BMI1 (B-cell-specific
Moloney murine leukemia virus integration site 1) induces resistance to conventional che‐
motherapy (docetaxel) [32], while PRC2 member EZH2 (enhancer of zeste homolog 2) is es‐
sential for PCa cell invasion and metastatic spreading [33].
As anticipated, trithorax group genes (TrxGs) were first discovered as PRC-counteracting
forces in Drosophila, where their role in switching on and maintaining the activation of HOX
genes is well known [30]. TrxG complex organization is more variable than what has been
found for PRCs. First, TrxGs include both histone modifiers and ATP-dependent chromatin
remodelling factors [34]. The first class acts by decorating histone tails with activating
marks, while the latter “reads” those modifications and actively induces a tridimensional
change in chromatin structure, which then becomes available for RNA polymerases and
transcription factors. Since this chapter is focused on strictly epigenetic mechanisms of gene
expression control, we will not discuss chromatin remodelling factors. In mammals, histone
modifier TrxGs are grouped in 3 major complexes (refer to Table 1): COMPASS (complex
protein associated with SET domain), COMPASS-like and ASH (absent small and homeotic
discs). COMPASS contains a histone methyltransferase domain (SET), which is shared with
PRC2 [35]. Unlike PRC2, COMPASS mediates H3K4me, a broad activating mark found
throughout the genome. COMPASS-like complexes also display the SET domain, which is
used to silence a more restricted group of genes [36]. COMPASS-like can also activate gene
expression through H4K16 acetylation [34]. Depending on subunit composition, this com‐
plex is also able to demethylate H3K27me, thereby directly counteracting PRC2 [37]. Finally,
ASH1 is able to catalyze H3K36me, a further activating mark. In mammals, this function is
mediated by a single protein rather than a complex [34].
Along with their function in embryonic development, TrxG histone modifiers are emerging
as a novel class of cancer-related genes [43]. Due to their multifaceted interaction with PcGs,
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and due to the role of PcGs in PCa, it is likely that TrxGs also play a role in this neoplasm.
For this reason, we decided to summarize current knowledge on the role of TrxGs in cancer
initiation and progression, and to query a publically available gene expression database, to
get insights into the role of those genes in PCa metastasis, which is the major determinant of
death induced by this neoplasm. Based on our literature search and our results, we will pro‐
pose a model to explain putative mechanisms of TrxG-dependent oncogenic, or tumor sup‐
pressive, functions.
Type Complex Subunits HPTMs Catalyzed Transcriptional
Effect
References
PcG PRC1 BMI1; RING1; RING1B; CBX H2AK119Ub Repression [38-40]
PRC2 EZH2; SUZ12; EED H3K27me3 Repression [38-40]
TrxG COMPASS SET1A,B; CXXC1; WDR82;
ASH2L*; DPY30; HCF1; RBBP5;
WDR5
H3K4me3 Activation [34, 41, 42]
COMPASS-like (A) MLL1,2; MOF; MENIN; ASH2L;
DPY30; HCF1; RBBP5; WDR5
H3K4me3;
H4K16ac
Activation [34, 41, 42]
COMPASS-like (B) MLL3,4; UTX; NCOA6; PA1; PTIP;
ASH2L; DPY30; HCF1; RBBP5;
WDR5
H3K4me3;
H3K27 demethylation
Activation [34, 41, 42]
ASH1 ASH1L H3K36me3;
H3K27ac
Activation [34, 41, 42]
Note : Red indicates core COMPASS subunits
Table 1. Composition and Activity of TrxG Complexes
2. Body
2.1. Overview of trithorax group activity in prostate cancer
It is now well established that TrxG counteracts PcG HPTMs to promote a transcriptionally
competent chromatin state [34, 44]. An intricate regulatory network controls whether the re‐
pressive effect of PcG activity or the activating role of TrxG dominates at specific loci [45].
The best characterized interplay between these two families of epigenetic modifiers occurs
during embryonic development. In undifferentiated cells, PcG is highly expressed and
maintains lineage-specific genes in a transcriptionally incompetent state while TrxG activity
is minimal [46]. In response to external differentiation cues, PcG activity is reduced while
TrxG becomes functionally active. As a result, lineage-specific genes are expressed and drive
the cell towards a differentiated state [46]. The classic example of TrxG and PcG interplay
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involves the regulation of the HOX locus(See Figure 1). First silenced by PcG in embryonic
stem cells (ESCs), HOX genes are subsequently induced upon TrxG activation during differ‐
entiation [47].
The functional relationship between PcG and TrxG is not limited to development. Incorrect
regulation of PcG and TrxG also plays an inherent role in cancer initiation and progression
[48-51]. In cancer, many embryonic transcriptional programs are orchestrated and push tu‐
mor cells towards a more undifferentiated state [43]. This directly implicates PcG and TrxG
as they regulate many common target tumor suppressor genes that inhibit differentiation,
invasion, and cell cycle progression [41]. These tumor suppressor genes are turned off in
cancer, correlating with increased PcG expression and H3K27 trimethylation [52]. This indi‐
cates that, in cancer cells, PcG somehow undergoes a gain of function while TrxG activity is
lost at key metastasis-inhibitory loci. In this classical model, PcG therefore act as oncogenes
while TrxG operate as tumor suppressors (See Figure 1).
Figure 1. Classical Model of the PcG-TrxG Interplay in Development and Cancer
However, this model does not explain all the data regarding TrxG in cancer as the expres‐
sion of individual TrxG subunits is highly heterogeneous across, and within, different tumor
types. According to the classical model, TrxG genes act as tumor suppressors and should
therefore be consistently downregulated in malignant cells. In fact, the expression of some
TrxG genes increases in cancerous tissues, suggesting an oncogenic role for these particular
TrxG genes [52, 53]. This indicates that there must exist an additional level of complexity
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which regulates not only the expression of individual TrxG genes, but also the activity and
sequence specificity of TrxG complexes. Since TrxG proteins function as multimeric struc‐
tures, their activity is highly context-dependent [54]. Many factors need to be taken into con‐
sideration when trying to assess the molecular function of TrxG complexes in a given
temporal and spatial context. First of all, what is the relative expression of the individual
subunits present within the TrxG complex? If many subunits are overexpressed or underex‐
pressed, the composition of the complex changes, which might lead to functional differen‐
ces. Second, which coregulators of these complexes are present? For example, a corepressor
could bind to a given TrxG complex and inhibit its H3K4 methyltransferase ability. Another
possibility is that a transcription factor expressed specifically in cancer cells binds to a TrxG
complex and recruits it to a normally untargeted loci. Finally, how is TrxG activity regulated
by PTMs of its individual subunits? Every TrxG complex is composed of multiple proteins,
all of them able to be chemically modified at multiple residues. Each PTM potentially affects
the activity of the complex and the additive effect of all these possible PTMs accounts for an
astronomical number of possible transcriptional outcomes [21]. In summary, although the
traditional model by which TrxG simply opposes PcG functions in cancer still represents a
good approximation, it remains incomplete as additional factors regulate TrxG activity.
Even though the epigenetic landscape of PCa remains quite complex, interesting links can
be found between histone modifiers and the metastatic process. PcG members EZH2 and
BMI1 are both overexpressed in PCa and their elevated expression correlates with metasta‐
sis and poor prognosis [55-57]. Their importance in PCa progression is reflected by the nu‐
merous studies that explored the possibility of targeting them pharmacologically [58-61].
While the role of PcG has been extensively investigated, few studies directly assessed the
role of TrxG in PCa. Our analysis revealed that although no individual TrxG genes shows
consistently significant up- or downregulation, a very high proportion of metastatic prostate
tumors contain at least one TrxG gene whose expression is deregulated. The accumulated
evidence suggests that TrxG does not act only as traditional tumor suppressors which coun‐
teract PcG activity. In fact, individual TrxG genes can interact with other complexes to either
promote or repress progression to metastasis. To account for this functional heterogeneity,
we will review the current literature for individual TrxG gene previously associated with
cancer and then discuss expression data from a publicly available PCa database. We will fin‐
ish by proposing putative mechanisms of TrxG misregulation in PCa, with a focus on the
metastatic process.
3. Literature review – Individual TrxG genes
3.1. ASH2L
ASH2L is the human homologue of Drosophila ASH2 (absent small homeotic 2) and repre‐
sents a core member of the COMPASS and COMPASS-like complexes. Through interactions
with WDR5 (WD-repeat protein 5) and RBBP5 (retinoblastoma binding protein 5), ASH2L
activates SET1 domain-containing proteins (SET1A, SET1B and mixed lineage leukemia
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(MLL)1-4) which subsequently catalyze H3K4 trimethylation [54]. The presence of ASH2L is
essential for optimal H3K4 trimethylation as knockdown of ASH2L led to a genome-wide
decrease in H3K4me3 [62]. Since COMPASS and COMPASS-like complexes are required for
the transcriptional activation of numerous differentiation genes such as the HOX family, de‐
fects in ASH2L activity result in developmental defects [42, 63]. In mice, homozygous
knockdown of ASH2L with gene-trap technology resulted in early embryonic lethality [64].
ASH2L also promotes differentiation in muscle during later developmental stages. Through
an interaction with ASH2L, PAX7 (paired box 7) recruits the WDR5-ASH2L-MLL2 complex
to myogenic gene promoters and promotes trimethylation of H3K4 at these sites [65].
MEF2D (myocyte enhancer factor 2D) is a transcription factor downstream of the p38 MAPK
(mitogen-activated protein kinase) that also directs ASH2L-containing complexes to MyoD
(myoblast determination protein)-bound genes in myoblasts [66]. At specific loci, MyoD,
PAX7, and ASH2L cooperate to induce a transcriptional program that leads to myogenic dif‐
ferentiation [67].
In addition to its role in development, ASH2L is also involved in tumor initiation. While
ASH2L mRNA levels remain normal in human cancers, ASH2L protein levels increase dra‐
matically in malignant cells, suggesting an oncogenic function for ASH2L [68]. Supporting
this hypothesis, ASH2L was also identified in complexes containing MYC (myelocytomato‐
sis viral oncogene homolog) oncogene [68]. Since MYC activity increases in many types of
cancers, the interaction between ASH2L and MYC suggests that ASH2L potentially adopts
an oncogenic function [69]. Indeed, ASH2L transforms primary rat embryo fibroblasts
(REFs) through cooperation with H-Ras (Harvey rat sarcoma viral oncogene homolog) [68].
As expected from an oncogene, knockdown of ASH2L reduces cell proliferation and inhibits
transformation of REFs by MYC and H-RAS [68]. A recent study revealed that ASH2L might
affect PCa progression by acting as a co-activator of the androgen receptor (AR) [70]. Co-
immunoprecipitation experiments showed that AR interacts with ASH2L [70]. Importantly,
TrxG genes MLL1 and MLL2 also interact with AR [70], suggesting that ASH2L function in
PCa results from association with complexes having H3K4 methyltransferase activity (See
Figure 2A). Furthermore, siRNA (small interfering RNA) silencing of MLL or ASH2L signifi‐
cantly repressed AR signalling [70]. However, pathways underlying the oncogenic nature of
ASH2L remain poorly characterized. An important question that needs to be addressed is
whether ASH2L promotes tumorigenesis through the same pathways in all tumor types or if
its activity depends on the availability of other context-specific coregulators.
3.2. MENIN
MENIN (protein encoded by multiple endocrine neoplasia 1 gene – MEN1) represents an in‐
tegral subunit of the COMPASS-like complex that contains MLL1-2, MOF (MYST family his‐
tone acetyltransferases), and core COMPASS proteins that trimethylate H3K4 [42]. In
contrast to ASH2L, whether MENIN acts as an oncogene or a tumor suppressor highly de‐
pends on the specific tissue. Inherited mutations inactivating the MEN1 gene lead to a con‐
dition called multiple endocrine neoplasia type 1, in which the patients develop neoplasias
in endocrine organs such as the parathyroid gland, the pituitary gland, and the pancreas [71,
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72]. In endocrine organs, MENIN functions as a tumor suppressor and its role has been well
characterized [73]. MENIN induces the transcription of cyclin-dependent kinase inhibitors
p18 and p27 [74]. A mutated MEN1 gene therefore leads to a decrease in p18 and p27 ex‐
pression, which accelerates cell-cycle progression. Loss of MENIN also promotes tumorigen‐
esis by releasing the inhibition of the oncogenic transcription factor JUN D (jun sarcoma
virus 17 oncogene homolog) [75], which subsequently induces the expression of genes re‐
sponsible for proliferation [76]. In summary, mutation of the MEN1 gene leads to neoplasm
formation in endocrine organs, which signifies that MENIN acts as a tumor suppressor in
these tissues. However, studies in hematopoietic malignancies containing MLL fusion pro‐
teins suggest an oncogenic role for MENIN [77]. In this context, MENIN binds to the MLL
fusion protein and the complex activates the expression of key oncogenes which drive leu‐
kemogenesis [78]. Since MLL fusion proteins do not possess a SET domain, it is important to
note that the oncogenic function of MENIN does not implicate H3K4 methylation [78]. Mis‐
regulation of MENIN activity also induces the formation of some solid tumors, although its
mechanism of action varies considerably with the tumor type. For example, MENIN has
been described as a tumor suppressor in non-small cell lung carcinomas (NSCLC) [79]. ME‐
NIN function can also be observed in other solid tumors. In breast cancer, MENIN repre‐
sents a transcriptional coactivator of ERα (estrogen receptor alpha). [80]. In MCF7 breast
cancer cells, MENIN co-localizes with ERα and activates ERα transactivation in a ligand-de‐
pendent manner [81]. Interestingly, MLL2 was also independently shown to associate with
ERα, suggesting that MENIN’s oncogenic function requires the methyltransferase activity of
its associated TrxG proteins [82]. Furthermore, ER-positive breast cancer samples highly ex‐
pressing MENIN had a worse outcome than those with low levels of MENIN after tamoxi‐
fen treatment [80]. These findings support the idea that MENIN overexpression promotes
the progression to a malignant phenotype in mammary tumors. As in breast cancer, MENIN
seems to function as an oncoprotein in PCa [53]. Significant upregulation of MENIN has
been described in metastatic prostate tumors in comparison with their non-metastatic coun‐
terparts [83]. Copy number gains for MEN1 represent frequent events in PCa and correlate
with an increase in MENIN levels [83]. Depletion of MENIN also significantly suppresses
proliferation of DU145 PCa cells, in addition to increasing the levels of Integrin-β1, CAS‐
PASE8, and p53 tumor suppressor [53]. Interestingly, MLL and MLL2 interact with AR.
Since MENIN associates with MLL and MLL2, it is possible that its oncogenic function
stems from cooperation with AR [70]. Given these findings, we propose that MENIN pro‐
motes tumorigenesis in PCa.
3.3. MLL
MLL is a H3K4 methyltransferase and its role has been well characterized in certain types of
leukemia where it is frequently involved in translocations [84]. Five MLL family members,
MLL1-5 are encoded in the mammalian genome [42]. MLL and MLL2 can associate with
MENIN, MOF and core TrxG subunits to form a complex with H3K4 and H4K16 methyl‐
transferase activity [54]. MLL3 and MLL4, on the other hand, can only be constituents of
TrxG complexes that contain UTX and therefore possess H3K27 demethylase activity [45].
MLL5 does not directly associate with core TrxG members and there is still no evidence that
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it has H3K4 methyltransferase activity [85]. The oncogenic role of MLL in leukemia arises
through a translocation that removes its SET domain responsible for H3K4 methylation [84].
However, the role of MLL in PCa tumors has not been fully studied yet. Recent reports indi‐
cate that MLL enhances androgen signalling by directly interacting with AR and trimethy‐
lating H3K4 at AR target genes [70]. In accordance with an activating role of MLL on AR
signalling, RNAi-mediated depletion of MLL significantly decreases Prostate-Specific Anti‐
gen (PSA) levels [70]. MLL expression is induced by SOX4 (Sex-determining region Y-box 4),
a transcription factor that also activates epidermal growth factor receptor (EGFR), Integrin
αv, Ras-related C3 botulinum toxin substrate 1 (Rac1), and ADAM metallopeptidase domain
10 (ADAM10) [86]. The pathways influenced by MLL activity suggest that MLL plays a role
in promoting tumorigenesis. As is the case with MLL, MLL2 has also been shown to interact
with AR. Although the role of MLL2 remains unclear in PCa, it seems to function as an on‐
coprotein in breast cancer [87]. By acting as a coactivator, MLL2 stimulates the transcription
of estrogen receptor (ER) target genes in ER+ breast tumors [88]. Amplification of MLL2 has
also been recorded in many solid malignancies including breast, pancreatic, brain, and ovar‐
ian tumors [89]. In summary, it seems that the H3K4 methyltransferase activity of MLL1 and
MLL2 mediates an oncogenic function in solid tumors.
Figure 2. Putative Mechanisms of Oncogenic TrxG Genes in PCa
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3.4. MOF
The acetyltransferase MOF (males absent on the first) associates with MENIN, MLL or
MLL2, and the core COMPASS proteins (ASH2L, DPY30, HCF1, RBBP5, and WDR5) to form
a distinct TrxG complex [90]. MOF specifically acetylates H4K16, a HPTM linked to tran‐
scriptional activation [91]. In cancer cells, loss of H4K16ac represents a common event and
correlates with general hypomethylation of repetitive DNA sequences [92]. This suggests
that MOF activity is inhibited in cancer cells and that MOF therefore functions as an onco‐
suppressor. Many important growth-regulatory pathways are regulated by MOF, some of
which do not require the H3K4 methyltransferase ability of COMPASS-like complexes. First
of all, MOF inhibits cancer progression by cooperating with forkhead box protein P3
(FOXP3) [93]. FOXP3 recruits MOF and the H3K4 methyltrasferase complex close to the
transcription start site of tumor suppressors [93]. The synergistic effect of H3K4 trimethyla‐
tion by MLL1-2 and of H4K16 acetylation by MOF results in transcriptional activation of tar‐
get loci. In addition to its regulatory function in transcription, MOF also plays an important
role in the DNA damage response (DDR), more specifically in the repair of double-stranded
breaks (DSBs) [94]. In response to ATM (ataxia telangiectasia mutated) pathway activation,
MOF gets recruited to chromatin where it acetylates H4K16 near DSBs [95]. At sites of DSBs,
MOF stimulates the activity of DNA-dependent protein kinases (DNA-PKcs), a critical com‐
ponent of non-homologous end-joining (NHEJ) [96]. Interestingly, studies demonstrated
that MOF inhibition also affects homologous recombination (HR) in addition to NHEJ [96].
In short, depletion of MOF leads to a reduction in H4K16 acetylation and is associated with
defective DNA repair and chromosomal aberrations following ionizing radiation [97]. MOF
also plays another critical role in DDR and apoptosis induction by acetylating the DNA-
binding domain of p53 at lysine 120 [98]. This modification leads to increased p53 stability
and triggers p53-mediated apoptosis through the upregulation of pro-apoptotic genes [99].
In summary, MOF acts as an important tumor suppressor in PCa through three distinct
mechanisms: 1) cooperating with FOXP3 to induce the expression of oncosuppressors 2) re‐
cruiting DDR proteins at DSBs by acetylating H4K16 and 3) acetylating p53 on lys120, lead‐
ing to the expression of pro-apoptotic genes (See Figure 3A).
3.5. UTX
UTX, also called KDM6 (histone lysine demethylase 6), associates with complexes contain‐
ing the H3K4 methyltransferases MLL3 or MLL4 [42]. UTX possesses H3K27 demethylase
activity and therefore plays a prominent role in the balance between PcG-mediated repres‐
sion and TrxG-mediated activation [100]. The role of UTX has been well characterized in
HOX gene regulation during embryonic development [101]. When a cell receives a differen‐
tiation signal, UTX promotes HOX gene expression in two ways: 1) It interacts with MLL3 or
MLL4, which catalyze the trimethylation of H3K4 at HOX loci and 2) It demethylates
H3K27me3, a chemical modification associated with transcriptional repression [101]. Aside
from its role in development, UTX has also been linked to cancer where it functions as a tu‐
mor suppressor [102]. The demethylase activity of UTX seems particularly relevant to PCa
as PRC2 gain of function and H3K27 trimethylation represent common hallmarks of aggres‐
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sive solid tumors [103].This global increase in H3K27me3 implies a loss of function for UTX
in PCa progression. UTX also counteracts PcG-mediated silencing by stimulating the ubiqui‐
tination of H2A, a HPTM associated with transcriptional activation [104]. Moreover, UTX
further antagonizes PcG function by interacting with BRM (ATP-dependent helicase brah‐
ma) and subsequently recruiting CBP (CREB-binding protein), which catalyzes H3K27 ace‐
tylation. The added acetyl group restricts the access to PRC2 at the modified sites and
therefore inhibits PcG-induced silencing [37]. UTX also plays an important role in repressing
cellular proliferation through the regulation of RB levels [105]. It promotes cell cycle arrest
by upregulating RB, a commonly altered tumor suppressor that inhibits the transcription of
genes responsible for G1/S transition [106]. In summary, UTX represses many molecular
processes associated with PCa initiation and progression (See Figure 3B). The tumor sup‐
pressive role of UTX has been validated in other tumor types. Systematic sequencing of re‐
nal carcinomas, multiple myelomas, medulloblastoma, and different types of leukemias all
revealed inactivating mutations in a significant number of patients [107-111] Furthermore,
UTX downregulation correlates with poor clinical outcome in breast cancer [112]. Given the
prominence of PcG in PCa, inactivation of UTX most likely represents a critical event in the
progression to metastasis.
Figure 3. Putative Mechanisms of Oncosuppressive TrxG Genes in PCa
3.6. WDR5
WDR5 represents a core member of the COMPASS and COMPASS-like complexes whose
functional role in cancer remains unclear [113]. To date, very few studies have focused sole‐
ly on the link between WDR5 and oncogenesis. However, WDR5 appears to have a promi‐
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nent role in embryogenesis. In ESCs, WDR5 interacts with the transcription factors OCT4
(octamer-binding transcription factor-4), SOX2, and NANOG to induce the expression of
genes necessary for pluripotency and self-renewal [114]. This transactivational ability corre‐
lates with H3K4 trimethylation at the target loci. Furthermore, somatic cell reprogramming
and formation of induced pluripotent stem cells (iPSCs) also requires the presence of WDR5
[114]. WDR5 has been shown to be essential for proper HOX gene activation as Xenopus Lae‐
vis tadpoles exhibit a wide range of developmental defects upon WDR5 depletion [115].
Moreover, WDR5 cooperates with the canonical Wnt pathway to induce osteoblast and
chondrocyte differentiation [116]. WDR5 is expressed upon bone morphogenetic protein
(BMP) signalling, another pathway associated with differentiation [117]. In fact, WDR5 was
initially called ‘‘BMP-2-induced gene 3 kb’’ and subsequently changed to its current name
[118].
Recently, a study demonstrated that WDR5 is induced under hypoxic conditions and is re‐
quired for epithelial-mesenchymal transition (EMT) [119]. Hypoxia activates the expression
of WDR5 and HDAC3. WDR5 and H3K4 methyltransferase complexes are then recruited to
promoters of mesenchymal genes to activate their transcription [119]. In parallel, HDAC3 re‐
moves pre-existing acetyl groups from H3K4 to potentiate WDR5 action. HDAC3 also re‐
moves histone acetylation marks from promoters of epithelial genes, further pushing the cell
towards a mesenchymal phenotype [119]. EMT represents an essential step for tumor meta‐
stasis [120-122]. Since WDR5 is required for EMT, WDR5 could potentially act as an onco‐
gene by promoting metastasis of primary prostate tumors (Figure 2B). Although the
oncogenic role of WDR5 has not been tested in PCa, studies in head and neck squamous cell
carcinoma showed that coexpression of HIF-1α, WDR5, and HDAC3 is associated with
metastasis and poor prognosis [119]. These results suggest that WDR5 functions as an onco‐
protein by triggering EMT. However, further studies are needed to assess the consequences
of WDR5 expression in PCa.
4. Expression data analysis and putative mechanisms of TrxG function in
malignant progression
As summarized in previous sections, epigenetic gene regulation plays a crucial role in PCa.
In particular, HPTMs mediated by TrxG genes are emerging as novel drivers of tumor pro‐
gression, or as mediators of tumor suppressive functions. Although these genes have been
extensively investigated in hematological neoplasms, their roles in solid tumors such as PCa
have not been completely elucidated. As demonstrated for other epigenetic players, it is
likely that The functioin of TrxG members is dependent on tissue type, tumor stage, as well
as on overlooked or uncharacterized determinants [123]. To gain insights into the possible
role of TrxG genes in PCa progression, we conducted an analysis of their expression in pri‐
mary vs. metastatic samples. To this aim, we exploited a publically available database
(http://www.cbioportal.org/public-portal/) [124]. Our results are summarized in Table 2. At
first glance, it is evident that each TrxG member represented in the table shows up- or
down-regulation in a relevant fraction (16-53%) of metastatic PCa cases. This indicates that
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aberrations in TrxG activity are likely to play an important role in the progression to meta‐
stasis.
TrxG Non-metastatic: 71/131 = 54% Metastatic: 18/19 Cases = 95%
ASH1L ↓ in 12/131 and ↑ in 1/131 = 10% ↓ in 5/19 = 26%
ASH2L ↓ in 13/131 and ↑ in 3/131 = 12% ↓ in 7/19 = 37%
WDR5 ↓ in 3/131 and ↑ in 5/131 = 6% ↓ in 9/19 and ↑ in 1/19 = 53%
MEN1 ↓ in 5/131 and ↑ in 19/131 = 19% ↓ in 10/19 = 53%
HCFC1 ↓ in 11/131 and ↑ in 14/131 = 19% ↓ in 4/19 and ↑ in 1/19 = 26%
MLL ↓ in 18/131 = 14% ↑ in 6/19 = 32%
MLL2 ↓ in 8/131 and ↑ in 12/131 = 15% ↓ in 4/19 and ↑ in 2/19 = 32%
MLL3 ↓ in 6/131 and ↑ in 3/131 = 7% ↓ in 2/19 and ↑ in 1/19 = 16%
MLL4 ↓ in 10/131 and ↑ in 10/131 = 15% ↓ in 6/19 = 26%
MLL5 ↓ in 6/131 = 5% ↓ in 1/19 and ↑ in 2/19 = 16%
UTX ↓ in 2/131 and ↑ in 6/131 = 6% ↑ in 5/19 = 26%
Table 2. CBio portal-derived gene expression data in primary vs. metastatic PCa. Arrows pointing up or down indicate
increased or decreased expression, respectively. The percentage indicates the fraction of alterted (up- or down-
regulated) genes.
In the following paragraphs, we will briefly discuss our findings and conciliate them with
published data on each TrxG memember.
1. ASHL: although ASH2L has been described as an oncoprotein [68], we found that
ASH-1L and -2L expression is reduced in metastatic PCa samples. This discrepancy
might be explained by the evidence that ASH2L protein levels rise in cancer, but mRNA
level does not increase [68]. This implies additional regulation at the translational level,
most likely relating to a defect in proteasomal degradation.
2. MEN1: MENIN can function as an oncogene [53, 78] and as a tumor suppressor [73] de‐
pending on tissue specificity. MENIN interacts with nuclear proteins like estrogen- and
vitamin D-receptor [80, 125], thereby stimulating their transactivation. Since other
members of the COMPASS-like complex interact with AR [70], we propose that the on‐
cogenic function of MENIN might result from its association with, and subsequent
stimulation of, AR transactivation ability through H3K4 trimethylation (See Figure 2).
Since most metastatic PCas are androgen-independent, while almost all primary tumors
display an active AR signaling [126], MENIN action is likely required in early tumor
stages. This explains the preferential up-regulation of MEN1 in non-metastatic (likely
androgen dependent) PCa samples (Table 2).
3. MLL: There is no documented role for MLL in PCa. Data from the cBio database shows
that MLL expression is increased in metastatic vs. primary PCa samples. Therefore we
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propose that MLL acts as a metastasis-driving oncogene in PCa. MLL is known to inter‐
act with AR [70]. Since metastatic PCa cells are usually AR-independent, the mecha‐
nism of MLL action in the metastatic process is likely androgen-independent too.
Interestingly, MLL homologs are often down-regulated in metastatic PCa (Table 2), sug‐
gesting that they might counteract its oncogenic function.
4. MOF: MOF was not included in the cBIO database, but based on its regulation of
growth suppressive pathways (See Figure 3), we propose that MOF acts as a tumor sup‐
pressor and therefore we expect to see its expression downregulated in PCa. However,
since MOF is required for optimal DNA damage response to double-stranded breaks
[96], reduced MOF expression could be a predictor of good response to radiotherapy or
to chemotherapy agents that induce dsDNA breaks.
5. UTX: The protein encoded by this gene possesses H3K27 demethylase activity, which
counteracts the repressive effect of PRC2-catalyzed H3K27me3. Due to the preponder‐
ance of PRC2 activity in PCa, UTX loss of function appears to be a critical event in the
progression to metastasis. UTX also interacts with other histone-modifying complexes
that catalyze HPTMs associated with transcriptional activation (See Figure 3). Despite
this evidence, we found an increased rate of UTX upregulation in metastatic vs. non
metastatic PCa samples (Table 2). Those data counteract the common view that UTX
acts as a tumor suppressor, at least in PCa. A possible explanation derives from the re‐
cent finding that UTX is frequently mutated in metastatic PCa [70]. It is worth noting
that all experiments on the oncosuppressive role of UTX have been performed on the
wild-type gene. We do not know whether the mutated protein simply loses its tumor-
suppressive activity, or if it acquires oncogenic features. In the latter case, the upregula‐
tion reported in metastatic PCa might even drive tumor progression.
6. WDR5: Although no studies have directly assessed the role of WDR5 in PCa, data from
ESC suggest that WDR5 might promote metastasis due to its implication in EMT. Dur‐
ing EMT, WDR5 promotes the expression of mesenchymal genes by stimulating H3K4
methylation at target loci [119]. Since WDR5 triggers EMT, we would expect its expres‐
sion to increase in metastatic samples. However, in the MSKCC database, WDR5 ex‐
pression is reduced in metastatic tumors. This could be explained by the fact that only a
subset of PCa cells acquires epigenetic alterations in response to cues from the extracel‐
lular environment (niche) which predisposes them to metastasis. Since only a minority
of the tumor bulk acquire invasive and migratory potential, the elevated expression of
WDR5 in those cells would not be detected by micro-array as the levels of WDR5 in
non-invasive cells would dominate.
The reader is cautioned that it is necessary to consider that studies comparing metastatic
and primary tumors might oversimplify the complex nature of the metastatic process. First,
those studies show expression levels of target genes at 2 specific time points, while the meta‐
static process occurs over several years in the clinical setting [58]. Second, molecular mecha‐
nisms of regulating metastasis are complex: if EMT is required as an early step, the opposite
(mesenchymal-to-epithelial transition) is needed during metastatic cell homing [127]. Thus,
a gene required during early metastatic steps might even be silenced at later stages. These
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considerations underscore the fact that our conclusions are limited, and need to be comple‐
mented by functional and clinical studies. However, results shown in Table 2 indicate that at
least some TrxG genes are likely involved in PCa metastasis and thus are candidate thera‐
peutic targets or prognostic factors.
5. Conclusion
While for many years cancers were thought to arise as a result of genetic alterations, an in‐
creasing number of studies report that in fact epigenetic misregulation primarily drives PCa
progression and metastasis [13, 128]. PcG proteins EZH2 and BMI1 are overexpressed in
PCa, an event that correlates with increased metastatic spreading and poor prognosis [57].
Since TrxG antagonizes PcG action, we explored the possibility that aberrant TrxG signal‐
ling could also represent a key factor in PCa metastasis. Since PcG is overactive in PCa and
TrxG counteracts PcG activity, TrxG were historically thought to be oncosuppressive [41].
Analysis of expression databases revealed that almost all metastatic prostate tumors show
deregulated expression of at least one TrxG gene. Interestingly, an in-depth literature review
combined with an analysis of expression data indicated that aberration in TrxG complexes
impacts PCa progression in a way that goes beyond their anticipated roles as classical tumor
suppressors. In fact, some TrxG genes show elevated expression in metastatic PCas and
have been shown to interact with, and enhance the activity of, known oncogenes such as
AR, c-MYC, h-RAS [68, 70]. The finding that TrxG genes can act as either oncogenes or tu‐
mor suppressors implies that the regulation of TrxG activity highly depends on the cellular
context [68, 129]. Changes in individual TrxG gene expression, availability of coregulators,
as well as post-translational modifications on both individual TrxG subunits and coregula‐
tors all regulate the functional output of TrxG complexes. These multiple levels of regulation
account for the highly diversified spectrum of molecular processes affected by TrxG activity,
and explain why some TrxG genes can act as oncogenes and others as tumor suppressors.
Since it is becoming increasingly clear that misregulated TrxG activity represents a key driv‐
er of PCa progression, an important question arises: How can TrxG complexes be targeted
clinically? Inhibiting core TrxG subunits like MLL, ASH2L, and WDR5 does not represent a
suitable strategy. TrxG complexes play many important physiological roles [130] and there‐
fore disrupting these core TrxG proteins would result in high toxicity. In fact, it is important
to recognize that TrxG activity is highly context-dependent and is controlled by many core‐
gulators. This context-dependency can be exploited in the search for new drug targets. An
interesting strategy to adopt would be to identify TrxG coregulators that are overexpressed
in PCa only. Inhibiting these coregulators would impair TrxG function in PCa cells specifi‐
cally while leaving normal cells unaffected. Since TrxG complexes can be oncogenic or tu‐
mor suppressive, two types of coregulators should be targeted clinically. The first represents
coactivators of oncogenic complexes and second, corepressors of oncosuppressive com‐
plexes. Pharmacologic disruption of both of these proteins would in theory limit the tumori‐
genic potential of aberrant TrxG signalling. To date, no such coregulators have been
described in PCa. The link between TrxG and PCa remains poorly characterized and many
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more studies are required to understand the impact of dysregulated TrxG on PCa progres‐
sion. Nonetheless, the implication of TrxG in PCa supports the idea that epigenetic altera‐
tions represent key drivers in the progression to metastatic disease.
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